News & Updates
Showing Multidisciplinary articles
Showing

Datopotamab deruxtecan improves survival in breast cancer patients not eligible for immunotherapy
First-line treatment with datopotamab deruxtecan (Dato-DXd) results in statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) compared with chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), as shown by the results of the phase III TROPION-Breast02 trial.
Datopotamab deruxtecan improves survival in breast cancer patients not eligible for immunotherapy
06 Nov 2025
High BMI tied to ulnar nerve entrapment development in nondiabetic individuals
A longitudinal study from Sweden shows an association between high BMI and the development of ulnar nerve entrapment (UNE) in a middle-aged cohort of individuals without diabetes from northern Europe, with over 25 years of follow-up.
High BMI tied to ulnar nerve entrapment development in nondiabetic individuals
06 Nov 2025
Amivantamab-lazertinib combo improves survival by reducing resistance mechanisms in NSCLC
An updated analysis of MARIPOSA reveals significant reductions in the incidence of MET and EGFR resistance alterations with first-line amivantamab plus lazertinib compared with osimertinib, with no upregulation in other resistance pathways, in patients with nonsmall cell lung cancer (NSCLC).






